annual relapse rates

ECTRIMS 2024: MS relapse rates fall with 5 years on Briumvi

Continuous treatment with Briumvi (ublituximab) over five years was associated with low rates of relapses and confirmed disability progression among people with relapsing forms of multiple sclerosis (MS), according to analyses from the open-label extension (OLE) phase of the treatment’s ULTIMATE Phase 3 trials. Relative to patients who…

Mavenclad lowers relapse rates, helps RRMS patients reach NEDA-3

Treatment with Mavenclad (cladribine), an approved short-course oral therapy for relapsing forms of multiple sclerosis (MS), significantly reduced patients’ relapse rates and the development of new lesions while keeping disability stable over two years, according to a real-world study in Kuwait. Among patients who completed the two courses…

Ocrevus appears to be better than rituximab at preventing MS relapses

Ocrevus (ocrelizumab) appears to be more effective than rituximab at reducing relapse activity in people with relapsing-remitting multiple sclerosis (RRMS), but disability progression outcomes are comparable between the therapies, an observational study of patients reported. “Study findings suggest that the effectiveness of rituximab on MS relapses was…

MSTOP Program in California Cuts DMT Costs and MS Relapse Rates

A program aimed at optimizing the use of highly effective therapies successfully lowered treatment costs and relapse rates among people with multiple sclerosis (MS) in Southern California, according to a study. “Our novel physician-led approach simultaneously reduced MS DMT [disease-modifying therapy] expenditures and the frequency of MS relapses. We…

#ECTRIMS2016 – Investigational Leustatin Tablets Offer Clinical Benefits to Different MS Patients

Leustatin (cladribine) tablets, an investigational drug, were shownĀ to be effectiveĀ at reducing annual relapse rates, not only in MS patients, but also inĀ patients with a first demyelinating event who later converted to a clinically defined multiple sclerosis diagnosis. The results were shared in a presentation titled ā€œCladribine tablets in the ORACLE-MS…